| 1 |
Chen Z, Li G, Liu J, et al. Autonomic dysfunction in Parkinson′s disease: Implications for pathophysiology, diagnosis, and treatment [J]. Neurobiol Dis, 2019, 134: 104700.
|
| 2 |
Chopek JW, Hultborn H, Brownstone RM, et al. Multistable properties of human subthalamic nucleus neurons in Parkinson′s disease [J]. Proc Natl Acad of Sci USA, 2019, 116(48): 24326-24333.
|
| 3 |
Wagenbreth C, Kuehne M, Heinze HJ, et al. Deep Brain Stimulation of the Subthalamic Nucleus Influences Facial Emotion Recognition in Patients With Parkinson′s Disease: A Review [J]. Front Psychol, 2019, 10: 2638.
|
| 4 |
Kordower JH. AAV2-Neurturin for Parkinson′s Disease: What Lessons Have We Learned? [J]. Methods Mol Biol, 2016, 1382: 485-490.
|
| 5 |
Hudry E, Vandenberghe LH. Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality [J]. Neuron, 2019, 101(5): 839-862.
|
| 6 |
Xiao W, Gao G, Ling C, et al. Impact of neutralizing antibodies against AAV is a key consideration in gene transfer to nonhuman primates [J]. Nat Med, 2018, 24(6): 699.
|
| 7 |
Tordo J, O′Leary C, Antunes ASLM, et al. A novel adeno-associated virus capsid with enhanced neurotropism corrects a lysosomal transmembrane enzyme deficiency [J]. Brain, 2018, 141(7): 2014-2031.
|
| 8 |
Blessing D, Déglon N. Adeno-associated virus and lentivirus vectors: a refined toolkit for the central nervous system [J]. Curr Opin Virol, 2016, 21: 61-66.
|
| 9 |
Wang C, Kang X, Zhou L, et al. Synaptotagmin-11 is a critical mediator of parkin-linked neurotoxicity and Parkinson′s disease-like pathology [J]. Nat Commun, 2018, 9(1): 81.
|
| 10 |
Yang H, Yang J, Xi W, et al. Laterodorsal tegmentum interneuron subtypes oppositely regulate olfactory cue-induced innate fear [J]. Nat Neurosci, 2016, 19(6): 862.
|
| 11 |
Loew KI, Aebischer P, Schneider BL. Direct and Retrograde Transduction of Nigral Neurons with AAV6, 8, and 9 and Intraneuronal Persistence of Viral Particles [J]. Hum Gene Ther, 2013, 24(6): 613-629.
|
| 12 |
Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles [J]. Science, 1965, 149(3685): 754-756.
|
| 13 |
Burger C, Gorbatyuk OS, Velardo MJ, et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential effificiency and cell tropism after delivery to different regions of the central nervous system [J]. Mol Ther, 2004, 10(2): 302-317.
|
| 14 |
Dodiya HB, Bjorklund T, Stansell J 3rd, et al. Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates [J]. Mol Ther, 2010, 18(3): 579-587.
|
| 15 |
Furman JL, Sama DM, Gant JC, et al. Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer′s disease [J]. J Neurosci, 2012, 32(46): 16129-16140.
|
| 16 |
Jonquieres G, Mersmann N, Klugmann CB, et al. Glial promoter selectivity following AAVdelivery to the immature brain [J]. PLoS One, 2013, 8(6): e65646.
|
| 17 |
Weller ML, Stone IM, Goss A, et al. Selective overexpression of excitatory amino acid transporter 2 (EAAT2) in astrocytes enhances neuro protection from moderate but not severe hypoxia-ischemia [J]. Neuroscience, 2008, 155(4): 1204-1211.
|
| 18 |
Samaranch L, Salegio EA, San Sebastian W, et al. Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates [J]. Hum Gene Ther, 2012, 23(4): 382-389.
|
| 19 |
Faustini G, Longhena F, Varanita T, et al. Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson′s disease [J]. Acta Neuropathol, 2018, 136(4): 621-639.
|
| 20 |
Grames MS, Dayton RD, Jackson KL, et al. Cre-dependent AAV vectors for highly targeted expression of disease-related proteins and neurodegeneration in the substantia nigra [J]. Faseb J, 2018, 32(8): 4420-4427.
|
| 21 |
Albert K, Voutilainen MH, Domanskyi A, et al. Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson′s disease [J]. J Neurosci Res, 2019, 97(3): 346-361.
|
| 22 |
Betley JN, Stemson SM. Adeno-Associated Viral Vectors for Mapping,Monitoring,and Manipulating Neural Circuits [J]. Hum Gene Ther, 2011, 22(6): 669-677.
|
| 23 |
Albert K, Voutilainen MH, Domanskyi A. AAV Vector-Mediated Gene Delivery to Substantia Nigra Dopamine Neurons: Implications for Gene Therapy and Disease Models [J]. Genes, 2017, 8(2). pii: E63.
|
| 24 |
何天齐, 李敏, 王雪楠, 等. 腺相关病毒应用于大鼠丘脑纹状体通路的研究 [J]. 山东大学学报(医学版), 2020, 58(3): 65-74.
|
| 25 |
Karin IL, Patrick A, Bernard LS. Direct and Retrograde Transduction of Nigral Neurons with AAV6, 8, and 9 and Intraneuronal Persistence of Viral Particles [J]. Hum Gene Ther, 2013, 24(6): 613-629.
|
| 26 |
Dirren E, Towne CL, Setola V, et al. Intracerebroventricular Injection of Adeno-Associated Virus 6 and 9 Vectors for Cell Type-Specific Transgene Expression in the Spinal Cord [J]. Hum Gene Ther, 2014, 25(2): 109-120.
|
| 27 |
Rocha EM, Smith GA, Park E, et al. Glucocerebrosidase gene therapy prevents a-synucleinopathy of midbrain dopamine neurons [J]. Neurobiol Dis, 2015, 82: 495-503.
|
| 28 |
Oh SM, Chang MY, Song JJ, et al. Combined Nurr1 and Foxa2 roles in the therapy of Parkinson′s disease [J]. EMBO Mol Med, 2015, 7(5): 510-525.
|
| 29 |
Sanftner LM, Sommer JM, Suzuki BM, et al. AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters [J]. Exp Neurol, 2005, 194(2): 476-483.
|
| 30 |
Johnston LC, Eberling J, Pivirotto P, et al. Clinically relevant effects of convection enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys [J]. Hum Gene Ther, 2009, 20(5): 497-510.
|
| 31 |
Kells AP, Eberling J, Su X, et al. Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF [J]. J Neurosci, 2010, 30(28): 9567-9577.
|
| 32 |
Hadaczek P, Eberling JL, Pivirotto P, et al. Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC [J]. Mol Ther, 2010, 18(8): 1458-1461.
|
| 33 |
Forsayeth JR, Eberling JL, Sanftner LM, et al. A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys [J]. Mol Ther, 2006, 14(4): 571-577.
|
| 34 |
Gasmi M, Brandon EP, Herzog CD, et al. AAV2- mediated delivery of human neurturin to the rat nigrostriatal system: long-term effificacy and tolerability of CERE-120 for Parkinson′s disease [J]. Neurobiol Dis, 2007, 27(1): 67-76.
|
| 35 |
Herzog CD, Dass B, Holden JE, et al. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys [J]. Mov Disord, 2007, 22(8): 1124-1132.
|
| 36 |
Kirik D, Cederfjäll E, Halliday G. Gene therapy for Parkinson′s disease: Disease modification by GDNF family of ligands [J]. Neurobiol Dis, 2017, 97(Pt B): 179-188.
|
| 37 |
Loew KI, Aebischer P, Schneider BL. Direct and Retrograde Transduction of Nigral Neurons with AAV6, 8, and 9 and Intraneuronal Persistence of Viral Particles [J]. Hum Gene Ther, 2013, 24(6): 613-629.
|